Drug Search Results
Using advanced filters...
Advanced Search [+]

Titanium dioxide

Alternative Names: titanium dioxide, ti-02, ti02, ti 02, anthelios 20, anthelios 40
Clinical Status: Inactive
Latest Update: 2025-07-08
Latest Update Note: News Article

Product Description

Titanium dioxide (TiO2) is a natural oxide of the element titanium with low toxicity, and negligible biological effects.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26996620/)

Mechanisms of Action: UV Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Topical,Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Croatia | Denmark | Ecuador | France | Hong Kong | India | Ireland | Israel | Italy | Malta | Morocco | New Zealand | Norway | Portugal | Sweden | Taiwan | United Arab Emirates | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Orfagen
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Titanium dioxide

Countries in Clinic: Egypt

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Dentin Sensitivity

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Fadia Ali El-Sayed Shosha

P1

Completed

Dentin Sensitivity

2023-03-15

2023-09-07

Primary Endpoints|Treatments